Lorlatinib, a third-generation’s ALK and ROS-1 inhibitor, as monotherapy is currently approved for the treatment of adult patients with ALK-positive advanced NSCLC, whose disease progressed on crizotinib and at least one other ALK inhibitor or on alectinib or ceritinib as first-line for metastatic disease [31]. This evidence concerns the gene ALK and non-small cell lung carcinoma.